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Recombinant factor VIIa (rFVIIa) has been widely
used in the treatment of bleeding episodes in he-
mophilic patients with inhibitors. Its mechanism
in hemostatic efficiency, however, is not fully un-
derstood.1 Factor VIIa plays a central role in initi-
ating the process of blood coagulation by forming
a complex with tissue factor (TF), when TF is ex-
posed to circulation due to the damage of blood
vessels.2 In such systems, therapeutic doses of
rFVIIa have been shown to induce normal throm-
bin generation and platelet activation in the ab-
sence of factors VIII and IX.3 Although rFVIIa was
designed for the treatment of hemophilic patients
with inhibitors to factors VIII and IX, it has also
been used “off-label” to enhance hemostasis in
nonhemophilic patients who experience bleeding
episodes unresponsive to conventional therapy.4
There have been anecdotal reports of the success-
gful use of rFVIIa in the control of life-threatenin
bleeding in patients with liver disease, but fail-
ures such as recurrent bleeding have also been
reported.5
Case Report
yA 68-year-old woman presented at our emergenc
rdepartment complaining of dyspnea and feve
cfor 1 week. Her medical history revealed chroni
hepatitis C virus (HCV) related liver cirrhosis, dia-
betes, hypertension and congestive heart failure.
Pneumonia over the right lower lung field was
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CASE REPORT
initially diagnosed. Diagnostic thoracentesis
from right pleural cavity disclosed parapneu-
monic effusion. Sudden onset of dyspnea and
hypotension developed 5 hours after the proce-
dure. Hemothorax was suspected because chest
radiographs showed rapid accumulation of right
side pleural effusion (Figure 1), and hemoglobin
decreased from 9.1 to 6.9 g/dL. A chest tube was
inserted into the right chest, and 1.6 L of uncoag-
ulable blood was drained out immediately. Surgi-
cal intervention was not suggested by the chest
surgeon due to the tendency of bleeding (interna-
tional normalized ratio (INR) 1.7 and thrombo-
cytopenia). The patient received blood transfusion
and was admitted to the intensive care unit (ICU)
in a stable condition on the same day.
In the ICU, physical examination showed a
pulse rate of 82/min, respiration rate of 24/min,
body temperature of 36.5°C and blood pressure of
120/70 mmHg under 6 μg/kg/min dopamine 
infusion. Pale conjunctivae and icteric sclerae were
noted. Chest wall expansion and breathing sounds
decreased over the right side. A chest tube was in-
serted into the right hemithorax with poor func-
tion. The abdomen was soft without tenderness.
The findings of other physical examinations were
unremarkable. Laboratory investigations showed
persistent anemia (hemoglobin, 7 g/dL), throm-
bocytopenia (33×103/μL), impaired liver function
(total/direct bilirubin, 2.54/1.8 mg/dL; alanine
aminotransferase, 1370 U/L; aspartate aminotrans-
ferase, 448 U/L) and bleeding tendency (INR, 2.1;
activated partial thromboplastin time (aPTT),
 55 seconds). Copious blood oozed from the
insertion wound of the chest tube, and hemoglo-
tbin remained low despite aggressive componen
ytherapy. Emergent angiography on the next da
showed a bleeder over the lateral portion of the
right fifth intercostal artery, and superselective em-
bolization with glue mixed with lipiodol was per-
formed. Postembolization angiography showed
no more bleeding (Figure 2). However, hemoglo-
bin remained low despite massive transfusion
(2.5 L packed red cells, 2.5 L fresh frozen plasma,
36 units platelets, 30 units cryoprecipitate) after the
procedure. On the basis of continuous intratho-
racic bleeding in the absence of a major bleeder,
two doses of rFVIIa 100 μg/kg/BW (7.2 mg/dose)
fwere administered intravenously at an interval o
2 hours. The bleeding from the chest tube wound
stopped immediately, and prothrombin time (PT)
returned to normal (INR, 1). No further blood
transfusion was required over the next 5 days
(Figure 3). Although blood pressure stabilized
fafter admission and dopamine was tapered of
on the 2nd rday of admission, the patient’s live
ffunction deteriorated gradually after the onset o
tshock. Hepatic failure progressed, and the patien
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A BiF gure 1. l hInitia  c est roentgeno-
graphy shows: (A) a pneumonic
patch over the right lower lung field
with parapneumonic effusion;
(B) 5 hours after the procedure, 
a rapid accumulation of right 
pleural effusion is apparent.
died of nosocomial infection and multiple organ
failure on the 12th day of hospitalization.
Discussion
The most common cause of hemothorax is
trauma. Other etiologies of hemothorax include
neoplasm (primary or metastatic), dissecting aor-
ytic aneurysm, coagulation disorders, pulmonar
embolism with infarction, catamenial and iatro-
genic disorders.6 The most common causes of ia-
trogenic hemothorax are perforation of a central
vein by a percutaneously inserted catheter, fol-
lowed by thoracentesis and pleural biopsy.6 Tube
ythoracostomy, thoracoscopy and thoracotom
f fTreatment o  hemothorax with actor VIIa
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A B
iF gure 2. f f f(A) Angiography shows a bleeder over the lateral portion o  the right i th intercostal artery. (B) Postembolization
angiography shows no more bleeding.
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iF gure 3. Hemoglobin dramatically
d stabilized withoutrecovered an
 the 5 days after twotransfusion in
Ia administration;doses of rFVI
est (international coagulation t
atio, INR) also transientlynormalized r
uring this time.normalized d
should be considered as needed in patients with
iatrogenic hemothorax as in patients with trau-
matic hemothorax. Angiographic embolization
may be an alternative choice to thoracotomy in
patients with massive bleeding from an intercostal
artery.7 This patient with massive and persistent
hemothorax had a bleeder identified at an inter-
costal artery, but did not receive surgical inter-
vention because of bleeding tendency. Although
selective embolization stopped the bleeding from
the intercostal artery, the patient’s hemoglobin
level did not increase even under aggressive trans-
fusion. However, bleeding ceased dramatically
after two doses of rFVIIa administration, and he-
moglobin did not decrease thereafter.
rFVIIa was originally used for the treatment 
of hemophilic patients with inhibitors to either
factor VIII (FVIII) or IX (FIX). It is also approved
for the treatment of acquired hemophilia, con-
genital FVII deficiency and Glanzmann’s throm-
basthenia in Europe.8 It is interesting to note that
there were many reports suggesting that this
product is safe and effective in controlling bleed-
ing in nonhemophilic patients.4 The treatment 
of hemothorax with rFVIIa in a nonhemophilic
patient unresponsive to conventional therapy has
not been previously reported. The mechanism of
action of rFVIIa is not completely clear. Small
quantities of FVIIa in circulation are not biologi-
cally active unless bound to TF that is exposed at
the site of the vascular injury. The complex of TF
and VIIa (TF-VIIa) initiates the coagulation cascade
by activating factors X and IX, resulting in the pro-
duction of a small amount of thrombin. Thrombin
leads to platelet activation as well as activation of
factors VIII, V and XI. The activated platelets pro-
vide the phospholipids surface and the factors
necessary for the production of a critical level of
thrombin, which in turn allows for the deposition
of fibrin and clot formation.1–3
The half-life of rFVIIa is 2.60–2.84 hours in
adults and is independent of dosage.9 Based on
clinical experience and pharmacokinetic studies,
the recommended dosing schedule of rFVIIa for
serious bleeding episodes and surgical coverage
is 90–120 μg/kg/BW, given at 2-hour intervals in
the first 24 hours until bleeding ceases.10 tMos
bleeding can be stopped with two to three doses.
That is why only two doses were given to this pa-
ttient. There is still no satisfactory laboratory tes
to monitor the clinical effectiveness of rFVIIa,
and shortening of PT and PTT does not necessar-
ily reflect in clinical effectiveness.11
frFVIIa has been used for the treatment o
bleeding in patients with liver disease.12 tMos
patients treated with rFVIIa have maintained
hemostasis, including rescue therapy in gastroin-
testinal or variceal bleeding, during liver trans-
cplantation and partial hepatectomy in noncirrhoti
patients, and on prophylactic use in patients un-
dergoing laparoscopic liver biopsy or colono-
scopic polypectomy.12 Other uses of rFVIIa
rinclude treatment of hereditary clotting facto
deficiencies,8 severe thrombocytopenia,13 tplatele
dysfunction,14 severe trauma,15 intractable bleed-
ing during surgery,16 life-threatening postpartum
hemorrhage,17 pulmonary hemorrhage,18 intracra-
nial hemorrhage19 and reversal of anticoagula-
tion intoxication.20 O’Connell et al21 reported a
series of nonhemophilia patients treated with
rFVIIa for major hemorrhages. Of the 40 patients
who received rFVIIa for uncontrolled hemorrhage,
bleeding either stopped or decreased in 32 (80%).
However, 23 (57.5%) of the 40 patients died from
tnonhemorrhagic causes. They concluded tha
rFVIIa was effective in nonhemophilia patients
ywith bleeding, but there was a high mortalit
rate from nonhemorrhagic causes.
It is likely that the safety of rFVIIa is due to
its selective location at the site of bleeding.
The incidence of serious adverse events due to
thromboembolism in hemophilic patients with
inhibitors is about 1%.22 The incidence in non-
hemophilic patients, however, is not known.
Many of the thrombotic events have occurred in
cpatients with a predisposition to thromboti
complications such as diabetes mellitus, obesity,
cancer and atherosclerotic cardiovascular disease,
and administration of rFVIIa to such patients
should be approached with caution.22 rFurthe
cstudy of the safety of rFVIIa use in hemophili
and nonhemophilic patients is warranted.
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The available evidence suggests that rFVIIa is
both safe and effective in hemophilic and non-
hemophilic conditions. This treatment appears
to be an attractive option in some patients ex-
periencing life-threatening hemorrhage, although
better delineation of its indications, including
safety, appropriate dosing and cost-benefit is
needed.
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